P1262: GILTERITINIB MAINTENANCE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA WITH FLT3–INTERNAL TANDEM DUPLICATION MUTATION
Topic: 22. Stem cell transplantation - Clinical Background: Patients with relapsed or refractory (r/r) acute myeloid leukemia (AML) with FLT3-Internal Tandem Duplication (ITD) mutation have a poor prognosis and high risk of relapse, even after allogeneic hematopoietic stem cell transplantation (HSCT). Prevention of disease relapse remains a challenge. Aims: To investigate the efficacy and tolerability of gilteritinib maintenance therapy post-transplantation in r/r AML patients with FLT3-ITD mutation. Methods: We compared different post-transplant maintenance therapies in 94 FLT3-ITD mutated r/r AML patients. A retrospective matched-pair analysis was performed. Patients were divided into two groups based on the maintenance therapy used, with 44 patients in the gilteritinib group and 50 patients in the control group (sorafenib/demethylating agents, or other targeted therapeutics were used as maintenance therapy). The therapeutic process and clinical outcome were retrospectively analyzed. Results: A total of 46.8% (44/94) of the patients had primary refractory disease and 42.6% (40/94) had recurrent AML. The remaining 10 patients were transplanted in CR1 but were detected with persistent MRD positivity during chemotherapy. Sixty-two patients (66.0%) were found to be MRD positive at the time of transplantation and 28 patients (29.8%) were transplanted with active disease. Gilteritinib maintenance therapy was associated with an improvement in overall survival (OS) (88.1% (95% CI 76.9-99.3%) vs. 65.1% (95% CI 51.6-78.6%), P=0.003) and relapse free survival (RFS) (75.7% (95% CI 62.6-88.8%) vs. 52.0% (95% CI 38.1-65.9%), P=0.006) at 2-years, when compared with the control group. Relapse remained the main reason of treatment failure with 2-year incidence of 25.4% (95%CI 12.7-40.2%) and 58.5% (95%CI 42.4-71.5%) for the gilteritinib group and the control group, respectively (P=0.004). Cumulative incidence of non-relapse mortality (NRM) at 2-years was similar (P= 0.744). In multivariate Cox regression analysis, gilteritinib maintenance therapy was the only factor associated with improved OS (HR=0.240, 95% CI 0.090–0.641, P=0.004) and RFS (HR=0.430, 95% CI 0.215–0.858, P=0.017). Cumulative incidence of day 100 aGVHD (P=0.083) and 2-year cGVHD (P=0.136) was comparable between the gilteritinib group and the control group. Summary/Conclusion: Our results indicated that gilteritinib maintenance therapy reduced the risk of relapse after HSCT for patients with FLT3-ITD mutated r/r AML. Compared with other maintenance therapies, gilteritinib treatment showed a similar incidence of NRM and GVHD, leading to an improvement in OS and RFS. Keywords: flt3 inhibitor, Maintenance, Allogeneic hematopoietic stem cell transplant, Acute myeloid leukemia